Department of Research, Dendreon Corporation, 1208 Eastlake Avenue East, Seattle, WA 98109, USA.
Expert Rev Clin Pharmacol. 2013 Jul;6(4):387-401. doi: 10.1586/17512433.2013.811814.
Immunotherapies are coming to the forefront as a treatment paradigm in cancer with multiple US FDA approvals in recent years and a better understanding of their therapeutic mode of action. The control of tumor growth by the immune system is orchestrated by a complex array of cellular interactions and molecular pathways, both in the immune cells as well as the tumor. Although research over the past three decades has elucidated many aspects of tumor immunosurveillance, given the inherent complexity of the immune cell phenotypes and function, high-throughput molecular profiling ('omics') approaches have now become essential to support the discovery and development of new therapies. Technologies, such as DNA and protein microarrays, deep sequencing, mass spectrometry, as well as the computational methods for their analyses, are advancing the contributions of systems biology towards the development and mechanistic understanding of cancer immunotherapies. In this review, the authors illustrate this through some recently reported studies.
免疫疗法作为癌症治疗模式正崭露头角，近年来有多项美国食品药品监督管理局(FDA)批准的免疫疗法药物上市，人们对其治疗作用模式的理解也更加深入。免疫系统控制肿瘤生长是通过一系列复杂的细胞相互作用和分子途径来实现的，这些作用既存在于免疫细胞中，也存在于肿瘤中。尽管过去三十年来的研究已经阐明了肿瘤免疫监视的许多方面，但鉴于免疫细胞表型和功能的固有复杂性，高通量分子谱分析（“组学”）方法现在对于支持新疗法的发现和开发已变得至关重要。DNA 和蛋白质微阵列、深度测序、质谱以及用于分析的计算方法等技术正在推动系统生物学对癌症免疫疗法的发展和机制理解做出贡献。在这篇综述中，作者通过最近报道的一些研究来说明这一点。
